Last $2.34 USD
Change Today -0.01 / -0.43%
Volume 14.7K
MELA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

mela sciences inc (MELA) Snapshot

Open
$2.38
Previous Close
$2.35
Day High
$2.38
Day Low
$2.29
52 Week High
10/25/13 - $10.40
52 Week Low
07/10/14 - $1.98
Market Cap
12.2M
Average Volume 10 Days
39.8K
EPS TTM
$-3.36
Shares Outstanding
5.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MELA SCIENCES INC (MELA)

Related News

No related news articles were found.

mela sciences inc (MELA) Related Businessweek News

No Related Businessweek News Found

mela sciences inc (MELA) Details

MELA Sciences, Inc., a medical device company, designs, develops, and commercializes a non-invasive point-of-care instrument to aid in the detection of melanoma. The company’s principal product, MelaFind, consists of a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions, which is then analyzed utilizing classification algorithms trained on its proprietary database of melanomas and benign lesions to provide information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion. MELA Sciences, Inc. offers its product to dermatologists. The company was formerly known as Electro-Optical Sciences, Inc. and changed its name MELA Sciences, Inc. in April 2010. MELA Sciences, Inc. was founded in 1989 and is based in Irvington, New York.

45 Employees
Last Reported Date: 03/17/14
Founded in 1989

mela sciences inc (MELA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $43.2K
Compensation as of Fiscal Year 2013.

mela sciences inc (MELA) Key Developments

MELA Sciences, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2014

MELA Sciences, Inc. announced unaudited financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $225,155 against $144,399 a year ago. Operating loss was $4,258,102 against $7,032,550 a year ago. Net income was $627,048 or $0.12 per diluted share against net loss of $7,421,754 or $1.72 per diluted share a year ago. The increase in revenue was due to new MelaFind(R) system sales as implement the change in the company's business model from a lease-based model to a sales-based model. Revenue increased due to new MelaFind(R) system sales as implement the change in the company's business model from a lease-based model to a sales-based model. A reduction in placement fees partially offset the increase in system sales. For the six months, the company reported revenue of $322,793 against $288,499 a year ago. Operating loss was $8,990,344 against $13,517,942 a year ago. Net loss was $7,353,548 or $1.46 per diluted share against $13,933,371 or $3.38 per diluted share a year ago. Net cash used in operating activities was $11,039,109 against $10,505,336 a year ago. The increase in revenue was due to the primarily change in business strategy from a lease-based model to a sales-based model, which resulted in sales for the current quarter and a decrease in placements of the MelaFind(R) systems quarter to quarter.

MELA Sciences, Inc. - Special Call

To provide an overview of the company as well as its lead product, the MelaFind System

MELA Sciences Names Michael R. Stewart to Board of Directors

MELA Sciences, Inc. announced it has named Michael R. Stewart to its board of directors effective immediately. Mr. Stewart is an independent director. Mr. Stewart served as president, chief executive officer and board member of NASDAQ-traded Surgical Laser Technologies, Inc. from 1999 until its sale in 2002 to global medical device and skin health company PhotoMedex. During his tenure as CEO of Surgical Laser, Mr. Stewart led all executive and internal operations, successfully transforming the company from a product sales model to a service model driving revenue and profit growth that positioned Surgical Laser Technologies for its ultimate sale to PhotoMedex, Inc. Post-acquisition and during his continuing tenure with PhotoMedex, Mr. Stewart has held the positions of chief operating officer and executive vice president and has led the domestic and international sales organizations, marketing, product development and engineering, manufacturing and service operations. He successfully developed and executed a reimbursement strategy for the company's dermatology product that resulted in the issuance of new Current Procedural Terminology codes and reimbursement by the Centers for Medicare and Medicaid Services and coverage policies with virtually all major insurance companies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MELA:US $2.34 USD -0.01

MELA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $15.82 USD -0.09
Verisante Technology Inc C$0.19 CAD +0.015
View Industry Companies
 

Industry Analysis

MELA

Industry Average

Valuation MELA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.5x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MELA SCIENCES INC, please visit www.melasciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.